Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.75M Buy
22,856
+713
+3% +$153K 0.13% 81
2026
Q1
$4.82M Buy
+22,143
New +$4.91M 0.14% 86
2025
Q2
$4.71M Sell
25,392
-3,508
-12% -$652K 0.22% 67
2025
Q1
$6.06M Buy
28,900
+2,365
+9% +$460K 0.29% 54
2024
Q4
$4.72M Buy
26,535
+8,194
+45% +$1.51M 0.24% 54
2024
Q3
$3.62M Sell
18,341
-369
-2% -$68.9K 0.19% 59
2024
Q2
$3.21M Buy
18,710
+5,533
+42% +$917K 0.18% 57
2024
Q1
$2.4M Buy
13,177
+6,208
+89% +$1.07M 0.15% 67
2023
Q4
$1.08M Buy
6,969
+550
+9% +$80.2K 0.07% 87
2023
Q3
$957K Sell
6,419
-441
-6% -$64.7K 0.07% 82
2023
Q2
$924K Buy
6,860
+341
+5% +$50K 0.07% 78
2023
Q1
$1.04M Sell
6,519
-155
-2% -$23.7K 0.08% 81
2022
Q4
$1.08M Sell
6,674
-1,196
-15% -$183K 0.09% 83
2022
Q3
$1.06M Buy
7,870
+612
+8% +$87.8K 0.1% 87
2022
Q2
$1.11M Buy
7,258
+1,287
+22% +$197K 0.1% 83
2022
Q1
$968K Sell
5,971
-292
-5% -$42.4K 0.03% 91
2021
Q4
$848K Sell
6,263
-442
-7% -$52.2K 0.03% 120
2021
Q3
$723K Buy
+6,705
New +$766K 0.03% 112
2021
Q1
$572K Buy
+5,282
New +$565K 0.05% 122

Other funds holding ABBV

E Fund Management's ABBV Position: Q2 2026 in Review

E Fund Management increased its AbbVie (ABBV) stake by 3.2% in Q2 2026, buying an estimated $153K and bringing the position to 22,856 shares worth $5.75M. The position accounts for 0.13% of the portfolio, ranked #81.

E Fund Management first reported a position in ABBV in Q1 2021 and has held it in 19 quarters since. The position peaked at $6.06M in Q1 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • E Fund Management held 22,856 shares of AbbVie worth $5.75M as of Q2 2026.
  • E Fund Management bought 713 AbbVie shares in Q2 2026, an estimated $153K.
  • AbbVie made up 0.13% of E Fund Management's portfolio in Q2 2026, its #81 holding.
  • E Fund Management first reported a position in AbbVie in Q1 2021 and has held it in 19 quarters since.
  • E Fund Management's AbbVie position peaked at $6.06M in Q1 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.